Researchers develop 'three-in-one' antibodies as a potential breakthrough intervention for HIV/AIDS

In a landmark study published in the journal Science recently, researchers produced genetically-engineered antibodies with the highest activity and breadth of coverage yet seen against human immunodeficiency virus (HIV-1).

In this study, conducted by researchers at France’s Sanofi and the US National Institutes of Health, antibodies were engineered to recognize three different target sites in one molecule. These HIV "trispecific" antibodies were highly effective in suppressing virus growth and

The trispecific antibodies showed better coverage than any previously-studied antibody, neutralizing 99% of more than 200 diverse strains of HIV-1. One of the trispecific antibodies that recognized the CD4 binding site, the membrane proximal external region (MPER), and the V1V2 glycan site of HIV fully protected monkeys against infection from a mixture of two simian/human immunodeficiency viruses (SHIV). These viruses had shown resistance to single-target antibodies